Kumar A, Mandhani A, Verma B S, Srivastava A, Gupta A, Sharma R K, Bhandari M
Department of Urology and Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
J Urol. 2000 Jan;163(1):33-6.
In a living related transplantation program it is not always possible to find an ideal donor. Sometimes the only available donor in the family has some benign disease or suboptimal renal anatomy or physiology, or is too old to be accepted and defined as a marginal donor. However, with proper screening the donor pool can be increased by accepting these marginal donors and treating the benign diseases which is beneficial to the donor. We evaluate the outcome of grafts from marginal donors.
From July 1988 to August 1997, 581 live related transplantations were performed. Of the donors 52 were older than 60 years and 34 had associated benign renal or nonrenal anomaly or disease. These donors were accepted after thorough questioning and consultation with family members. The recipients of graft from elderly donors were evaluated for the number of rejections, serum creatinine at last followup and graft survival.
Of the recipients 52 received grafts from elderly donors with a mean age of 62.6+/-3.7 years. Mean followup was 34.14+/-0.7 months. The 2 and 5-year actuarial graft survival was 96% and 74%, respectively. Creatinine was normal (less than 1.5) in 37% of recipients and 1.5 to 2.5 mg.% in 46%. The rejection rate in postoperative month 1 was 29%. All donors underwent simultaneous surgery to treat the benign disease, and all did well after surgery.
By accepting these marginal donors a 14.6% increase in the living related donor pool was achieved without compromising recipient or donor safety. Otherwise these recipients would have been forced to undergo unrelated transplantation or be maintained on dialysis, which is particularly difficult in a developing country. Donors with associated disease benefited from cure.
在活体亲属移植项目中,并非总能找到理想的供体。有时家庭中唯一可用的供体患有某些良性疾病,或肾脏解剖结构或生理功能欠佳,或年龄过大而不被接受,被定义为边缘供体。然而,通过适当的筛查,接受这些边缘供体并治疗良性疾病可增加供体库,这对供体有益。我们评估了边缘供体的移植物结局。
1988年7月至1997年8月,进行了581例活体亲属移植。其中供体52例年龄超过60岁,34例伴有良性肾脏或非肾脏异常或疾病。这些供体在经过彻底询问并与家庭成员协商后被接受。对老年供体移植物的受者进行排斥反应次数、末次随访时血清肌酐水平及移植物存活情况的评估。
52例受者接受了平均年龄为62.6±3.7岁的老年供体的移植物。平均随访时间为34.14±0.7个月。2年和5年的移植物精算存活率分别为96%和74%。37%的受者肌酐正常(低于1.5),46%的受者肌酐为1.5至2.5mg.%。术后第1个月的排斥反应发生率为29%。所有供体均同时接受了治疗良性疾病的手术,术后恢复良好。
通过接受这些边缘供体,活体亲属供体库增加了14.6%,且未损害受者或供体的安全。否则,这些受者将被迫接受非亲属移植或维持透析,这在发展中国家尤为困难。伴有疾病的供体也因疾病治愈而受益。